Takeda Sells U.S. Blood-Pressure Drug Rights To Arbor Pharma
This article was originally published in PharmAsia News
Executive Summary
Takeda Pharmaceutical plans to sell to Arbor Pharmaceuticals U.S. development and marketing rights to blood pressure drugs Edarbi (azilsartan) and Edarbyclor (azilsartan-chlorthalidone).